Keel
Metabolic & GLP-1

Semaglutide

Semaglutide is a peptide that mimics a natural gut hormone involved in blood sugar control and appetite. It's approved by the FDA under the brand names Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management, and it's one of the most extensively studied medications in this class.

Classification
GLP-1 receptor agonist
Format
Injectable solution or oral tablet
Half-Life
Approximately 7 days

What Is Semaglutide?

Semaglutide is a synthetic version of a hormone the body naturally produces called GLP-1, short for glucagon-like peptide-1. GLP-1 is released from the gut after eating and plays a role in regulating blood sugar and signaling fullness to the brain.[1] Semaglutide is built to mimic that hormone's activity while lasting far longer in the body than natural GLP-1, which normally breaks down within minutes.

Unlike most of the compounds covered on this site, semaglutide isn't a research-only peptide. It's an FDA-approved medication with one of the largest human clinical trial programs of any drug in its class, spanning both diabetes management and weight management indications.

What Semaglutide Is Being Researched For

  • Blood Sugar Control

    Semaglutide's original approval was for type 2 diabetes, based on its ability to lower blood sugar by increasing insulin release and reducing glucagon, a hormone that raises blood sugar.[1]

  • Body Weight

    A large body of clinical trial data, most notably the STEP trial program, has examined semaglutide's effect on body weight in people with overweight or obesity.[2]

  • Cardiovascular Outcomes

    A large-scale trial in people with cardiovascular disease and overweight or obesity, but without diabetes, found that semaglutide reduced the rate of major cardiovascular events compared to placebo over roughly three years of follow-up.[3]

How Semaglutide Works

  • Mimicking GLP-1 Signaling

    Research points to semaglutide binding to the same receptor as the body's natural GLP-1 hormone, which triggers increased insulin release and reduced glucagon release in response to food, helping regulate blood sugar after meals.[1]

  • Slowing Digestion and Signaling Fullness

    Research points to semaglutide slowing how quickly food moves through the stomach and acting on appetite-regulating areas of the brain, which together are tied to reduced food intake in clinical trials.[2]

  • Lasting Longer in the Body

    Research points to structural modifications in semaglutide that allow it to resist the enzymes that break down natural GLP-1 within minutes, extending its activity to about a week and enabling once-weekly dosing.[1]

Reconstitution and Handling

Semaglutide is available in FDA-approved pre-filled pen formulations, but research-grade vials sold as lyophilized powder are also common and require reconstitution with bacteriostatic water before use. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Once reconstituted, the solution is kept refrigerated to help preserve its stability.

Key Takeaways

Semaglutide stands apart from most compounds covered on this site because it's an FDA-approved medication with an unusually large and well-documented human clinical trial base, spanning diabetes, weight management, and cardiovascular outcomes. Its core mechanism centers on mimicking the body's natural GLP-1 hormone while resisting rapid breakdown, extending its activity from minutes to roughly a week. Research continues to expand into areas beyond its original approvals.

Clinical Overview

Evidence Summary

  • RCT

    In adults with overweight or obesity without diabetes, once-weekly semaglutide 2.4 mg produced a mean weight reduction of roughly 15% over 68 weeks versus about 2.4% with placebo in the STEP 1 trial.[2]

  • RCT

    In patients with established cardiovascular disease and overweight or obesity but without diabetes, semaglutide 2.4 mg reduced the incidence of major adverse cardiovascular events by about 20% versus placebo over a mean of roughly three years in the SELECT trial.[3]

  • RCT

    In type 2 diabetes, semaglutide lowers HbA1c and body weight through glucose-dependent stimulation of insulin secretion and suppression of glucagon, consistent with the established pharmacology of GLP-1 receptor agonism.[1]

  • Human

    Gastrointestinal adverse events, principally nausea, vomiting, diarrhea, and constipation, are the most frequently reported effects and are the leading cause of treatment discontinuation across the clinical program.[2][6]

Pharmacokinetics

  • Route

    Available as a once-weekly subcutaneous injection and as a once-daily oral tablet co-formulated with an absorption enhancer; the subcutaneous form has substantially higher and more consistent bioavailability than the oral form.[5]

  • Half-Life

    Terminal elimination half-life is approximately 7 days (roughly 155-184 hours), which supports once-weekly subcutaneous dosing.[5]

  • Time to Steady State

    Steady-state exposure is reached after approximately 4 to 5 weeks of once-weekly dosing, which underlies the stepwise dose-escalation schedule used to limit gastrointestinal effects.[5]

  • Metabolism and Clearance

    Cleared primarily through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty-acid side chain rather than by a single organ; albumin binding via the acylated side chain slows degradation and renal clearance.[1][5]

Contraindications and Interactions

  • The FDA label lists a personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 as contraindications, based on rodent C-cell tumor findings.[7][8]
  • The label contraindicates use in patients with a known serious hypersensitivity reaction to semaglutide or any product excipient.[7][8]
  • The label describes pancreatitis as a warning; it advises against use in patients with a history of pancreatitis in some trials and prompt evaluation and discontinuation if pancreatitis is suspected.[7][8]
  • Delayed gastric emptying can alter the absorption of concomitantly administered oral medications; the label notes this for orally administered drugs.[7][8]
  • The label states that concomitant insulin or a sulfonylurea increases the risk of hypoglycemia and that a dose reduction of the concomitant agent may be required.[7][8]
  • The label advises discontinuing semaglutide at least 2 months before a planned pregnancy given the long half-life; safety in pregnancy and lactation is not established.[7]

Monitoring Parameters

  • The label references HbA1c and fasting glucose assessment in patients treated for glycemic control.[8]
  • The label directs monitoring for symptoms of pancreatitis (persistent severe abdominal pain, with or without vomiting) and prompt evaluation if suspected.[7][8]
  • The label notes that acute kidney injury has occurred, often in the setting of dehydration from gastrointestinal adverse reactions; monitoring renal function is advised in patients reporting severe reactions.[7][8]
  • In patients on insulin or sulfonylureas, the label advises monitoring for hypoglycemia and adjusting concomitant therapy.[7][8]
  • The label advises monitoring patients with a history of diabetic retinopathy for progression, as rapid glycemic improvement has been associated with transient worsening.[8]
  • Cholelithiasis and cholecystitis have been reported with GLP-1 receptor agonists and rapid weight loss; the label lists gallbladder events among adverse reactions.[6][7]

Reported Adverse Events

  • Nausea, vomiting, diarrhea, and constipation, most pronounced during dose escalation.[2][6]
  • Abdominal pain and dyspepsia.[2]
  • Cholelithiasis and cholecystitis, associated with GLP-1 therapy and rapid weight loss.[6]
  • Acute pancreatitis (uncommon).[6]
  • Hypoglycemia when used with insulin or sulfonylureas.[1]

Frequently Asked Questions

What Is Semaglutide Derived From?

It's a synthetic version of GLP-1, a hormone the body naturally releases from the gut after eating.

What Is Semaglutide Approved For?

It's FDA-approved for type 2 diabetes under the brand names Ozempic and Rybelsus, and for weight management under the brand name Wegovy.

How Is Semaglutide Different from Tirzepatide?

Semaglutide acts on one receptor, the GLP-1 receptor. Tirzepatide acts on two, GLP-1 and GIP, which is one reason the two drugs are often compared in clinical trials.

Has Semaglutide Been Studied for Anything Beyond Diabetes and Weight?

Yes. A large cardiovascular outcomes trial found it reduced major cardiovascular events in people with existing heart disease and overweight or obesity, independent of a diabetes diagnosis.

Sources and Research

  1. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756.
  2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
  3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232.
  4. Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844.
  5. Overgaard RV, Navarria A, Ingwersen SH, Bækdal TA, Kildemoes RJ. Clinical Pharmacokinetics of Oral and Subcutaneous Semaglutide. Clin Pharmacokinet. 2021;60(10):1335-1348.
  6. Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023;330(18):1795-1797.
  7. WEGOVY (semaglutide) injection prescribing information. Novo Nordisk Inc.
  8. OZEMPIC (semaglutide) injection prescribing information. Novo Nordisk Inc.

Related Reading

For educational and research purposes only. Not medical advice. Always consult a licensed healthcare professional before starting any protocol.